SUFU (Suppressor of fused homolog) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Lung cancer, Medulloblastoma and 3 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
Negative regulator in the hedgehog/smoothened signalling pathway that acts by sequestering the GLI (GI1, GLI2 and GLI3) transcription factors in the cytoplasm. When smoothened signalling is initiated, GLI transcription factors dissociate from SUFU, translocate to the nucleus and activate expression of target genes. In absence of smoothened signalling, the SUFU-GLI3 complex is recruited to cilia, leading to the efficient processing of full-length GLI3 into transcription repressor GLI3R: SUFU participates to GLI3 processing by promoting recruitment of GSK3B to GLI3. May also act as a negative regulator of beta-catenin signalling. Required for normal embryonic development. Required for the proper formation of hair follicles and the control of epidermal differentiation. Location: Cytoplasm; Nucleus; Cell projection, cilium (UniProt). Locus 10q24.32 (HGNC).
- Skin cancer: Open Targets association 0.57 with skin cancer (MONDO_0002898)
- Lung cancer: Open Targets association 0.51 with lung cancer (MONDO_0008903)
- Medulloblastoma: Open Targets association 0.80 with medulloblastoma (MONDO_0007959); CIViC evidence names this disease
- Meningioma: Open Targets association 0.72 with meningioma (MONDO_0016642)
- Paediatric low-grade glioma: IntOGen driver in 1 cohort (PAST)
- Melanoma: Open Targets association 0.54 with melanoma (MONDO_0005105)
External identifiers
Built from HGNC, Ensembl, UniProt and ChEMBL idsProducts by modality and phase
Browse products →No product in the corpus is aimed at this target yet.
Trials
Evidence ranking →No trial in the corpus names this target or one of its products.
Resistance routes
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Literature
Preprints →Query for this target: (TITLE:"SUFU" OR ABSTRACT:"SUFU" OR TITLE:"SUFU negative regulator of hedgehog signaling" OR ABSTRACT:"SUFU negative regulator of hedgehog signaling" OR TITLE:"Suppressor of fused homolog" OR ABSTRACT:"Suppressor of fused homolog" OR TITLE:"SUFUH" OR ABSTRACT:"SUFUH" OR TITLE:"SUFUXL" OR ABSTRACT:"SUFUXL" OR TITLE:"PRO1280" OR ABSTRACT:"PRO1280") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SUFU, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/sufu.json. Licence CC BY-NC 4.0.